Poseida Therapeutics Inc (NAS:PSTX)
$ 3.46 0.54 (18.49%) Market Cap: 335.37 Mil Enterprise Value: 156.25 Mil PE Ratio: 0 PB Ratio: 2.69 GF Score: 35/100

Poseida Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 26, 2023 / 12:45PM GMT
Release Date Price: $2.38 (+13.64%)
Jennifer Kim
Cantor Fitzgerald - Analyst

For our next presentation. Hi, everyone. Welcome. I'm Jennifer Kim, one of the research analysts at Cantor Fitzgerald, and I'm looking forward to hosting Mark Gergen, the CEO and Chairman of Poseida Therapeutics.

Mark, thanks for joining us.

Mark Gergen
Poseida Therapeutics - CEO and Chairman

Well, thanks for having us, Jennifer. Happy to be here.

Jennifer Kim
Cantor Fitzgerald - Analyst

Okay. Happy to have you here. So, maybe as an intro for those less familiar with the story, do you want to give a brief background of yourself and the company?

Mark Gergen
Poseida Therapeutics - CEO and Chairman

Sure. I won't bore them too much. I'm the, obviously, the Chairman and CEO. Started as the CFO about five years ago. I've been in healthcare 30 years and biotech 25 years. Probably most notable, I was at Amylin Pharmaceuticals up to the sale to BMS in 2012. And then I helped to start a company now called Mirati Therapeutics.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot